A group of 21 Republican AGs sent a letter to the U.S. Drug Enforcement Administration requesting emergency action to schedule bromazolam under the Controlled Substances Act. The letter describes bromazolam—an unregulated benzodiazepine that is often referred to as “designer Xanax”—as “highly potent and unpredictable” and “particularly lethal for unsuspecting users” because of its unregulated status,…

Read More

Texas AG Ken Paxton has sued pharmaceutical manufacturer Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe and continue prescribing several Lilly drugs—including GLP-1 medications Mounjaro and Zepbound—in violation of the Texas Health Care Program Fraud Prevention Act. According to the complaint, Eli Lilly offered improper incentives to medical providers in Texas—such…

Read More

Connecticut AG William Tong announced a settlement with Triggered Brand following allegations that the company unlawfully advertised and sold counterfeit GLP-1 weight loss drugs in violation of state consumer protection laws.

Read More

In Law.com, Keturah Taylor predicts enforcement will broaden in the GLP-1 space and encourages legitimate players to engage early with state AGs.

Read More

New York AG Letitia James, along with a bipartisan coalition of 48 other AGs and in coordination with the U.S. DOJ, announced a $202 million settlement in principle with Gilead Sciences, Inc. (“Gilead”), to resolve allegations that the company ran an illegal kickback scheme to promote medications. According to the AG’s press release, Gilead violated…

Read More